A phase I, open-label, dose-escalation trial to evaluate the safety and tolerability of the combination of orally received pazopanib once every other day with continuous daily dosing of lapatinib in patients with solid tumours

Trial Profile

A phase I, open-label, dose-escalation trial to evaluate the safety and tolerability of the combination of orally received pazopanib once every other day with continuous daily dosing of lapatinib in patients with solid tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Pazopanib (Primary) ; Lapatinib
  • Indications Bladder cancer; Head and neck cancer; Liver cancer; Lung cancer; Non-small cell lung cancer; Sarcoma; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top